-
Product Insights
NewNet Present Value Model: Kezar Life Sciences Inc’s Zetomipzomib Maleate
Empower your strategies with our Net Present Value Model: Kezar Life Sciences Inc's Zetomipzomib Maleate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Kezar Life Sciences Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kezar Life Sciences Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Famitinib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Famitinib in Triple-Negative Breast Cancer (TNBC) Drug Details: Famitinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Systemic Lupus Erythematosus Drug Details: Zetomipzomib maleate is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Autoimmune Hepatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Autoimmune Hepatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Autoimmune Hepatitis Drug Details: Zetomipzomib maleate is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zetomipzomib Maleate in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zetomipzomib Maleate in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zetomipzomib Maleate in Lupus Nephritis Drug Details: Zetomipzomib maleate is under development...
-
Product Insights
Polymyositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Polymyositis - Drugs In Development, 2023’, provides an overview of the Polymyositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polymyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dermatomyositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatomyositis - Drugs In Development, 2023’, provides an overview of the Dermatomyositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lupus Nephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Lupus Nephritis - Drugs In Development, 2023’, provides an overview of the Lupus Nephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...